A se­r­i­al biotech start­up team is back in busi­ness, armed with $40M and a fo­cus on NASH

Bob Bal­tera’s last stint as a biotech CEO was brief. In less than a year at the helm of La­gu­na he and the com­pa­ny pro­duced some in­ter­est­ing late-stage da­ta and a trou­bling set of safe­ty is­sues that scut­tled their work on atri­al fib­ril­la­tion.

“We shut that down and gave about half of the mon­ey (which would have been about $15 mil­lion) back to the in­vestors,” he tells me in an ex­pe­ri­enced tone that sug­gests some things in this busi­ness just don’t work out the way you want it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.